Eli Lilly & Co. (LLY) Reports In-Line Q3 EPS; Narrows FY11 EPS Outlook
Tweet
Share
E-mailGet Alerts LLY Hot Sheet
Price: $1,208.12 +7.13%
EPS Growth %: +39.6%
Financial Fact:
Marketing, selling, and administrative: 1.57B
Today's EPS Names:
CGEH, NAKA, APOG, More
EPS Growth %: +39.6%
Financial Fact:
Marketing, selling, and administrative: 1.57B
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Eli Lilly & Co. (NYSE: LLY) reported Q3 EPS of $1.13, in-line with the analyst estimate of $1.13. Revenue for the quarter came in at $0 versus the consensus estimate of $6.06 billion.
Eli Lilly & Co. sees FY2011 EPS of $4.30-$4.35, versus prior guidance of $4.25-$4.35 and the consensus of $4.33.
Eli Lilly & Co. sees FY2011 EPS of $4.30-$4.35, versus prior guidance of $4.25-$4.35 and the consensus of $4.33.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
- H.B. Fuller (FUL) Tops Q2 EPS by 3c; Offers Outlook
- Eli Lilly plans European weight-loss pill launch by early 2027
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
